BACKGROUND Finasteride was introduced to treat patients with benign prostatic hyperplasia (BPH) recently, and it has shown its effects in reduction of prostate volume and decrease of prostate-specific antigen (PSA). We want to know how and how much does finasteride affect prostate volume as well as PSA and prostate-specific antigen density (PSAD), since PSA and PSAD are widely used as screening...

AIMS To describe the prostatic adenectomy specimens of six patients with symptomatic benign prostatic hyperplasia (BPH) who failed to respond to long term treatment with a 5-alpha-reductase inhibitor, finasteride. METHODS Histological sections from six cases of BPH who had been treated with finasteride were investigated. Five patients were prescribed 5 mg finasteride daily for six months and ...

To better understand the effects of antiandrogens on the prostate, we investigated the changes in the proteome of rat ventral prostate (VP) following treatment with a well characterized 5 -reductase inhibitor, finasteride. Sprague-Dawley rats were treated daily by gavage with finasteride at 0, 1, 5, 25, and 125 mg/kg/day. Changes in plasma hormone levels as well as the weight and histology of s...

INTRODUCTION Hematuria secondary to benign prostatic hyperplasia (BPH) can occur due to a vascular primary gland itself or due to the vascular re-growth of the prostate following a transurethral resection of the prostate (TURP). We aim to evaluate the clinical presentation and management in patients within both these groups. MATERIALS AND METHODS We retrospectively archived the data of 166 me...

Prostate cancer management has focused on early detection and treatment, but the prolonged development cycle of prostate cancer suggests that prevention may be a preferable approach. Finasteride and dutasteride, inhibitors of 5 -reductase, inhibit conversion of testosterone to dihydrotestosterone (a potent androgen) and have low toxicity, which makes them attractive chemopreventive agents. Both...

Androgenic alopecia (AGA), scalp hair loss, occurs due to the hyperactivity of steroid 5α-reductase2 (SRD5A2), which metabolizes testosterone into 5α-dihydroxytestosterone. Finasteride, an FDA-approved drug producing many side effects, is a commonly used competitive inhibitor for SRD5A2 treat AGA. As number mushroom species have been patients having loss problems since ancient times, in present...

Despite all modern surgical techniques, skin flap that is considered as the main method in most reconstructive surgeries puts the skin tissue at danger of necrosis and apoptosis derived from ischemia. Therefore, finding a treatment for decreasing the apoptosis derived from flap ischemia will be useful in clinic. In present study, we evaluated the effect of azelaic acid 20% and finasteride on ex...

Serum concentrations of neuroactive androgens decline in older men and, in some studies, low testosterone is associated with decreased cognitive function and incidence of depression. Existing studies evaluating the effect of testosterone administration on cognition in older men have been largely inconclusive, with some studies reporting minor to moderate cognitive benefit, while others indicate...

Purpose: Previous studies have demonstrated a negative correlation between prostate volume and biopsy yield. By decreasing prostate volume, 5α-reductase inhibitors may enhance cancer detection, which may explain the greater detection of high-grade tumors in the finasteride arm of the Prostate Cancer Prevention Trial (PCPT). Materials and Methods: A mathematical model was constructed analyzing t...

To better understand the effects of antiandrogens on the prostate, we investigated the changes in the proteome of rat ventral prostate (VP) following treatment with a well characterized 5alpha-reductase inhibitor, finasteride. Sprague-Dawley rats were treated daily by gavage with finasteride at 0, 1, 5, 25, and 125 mg/kg/day. Changes in plasma hormone levels as well as the weight and histology ...